NCT05364879

Prehabilitation for Ovarian Cancer Patients

Recruiting now NA Last updated 13 February 2025

What this trial tests

NA trial testing Prehabilitation Exercise Intervention in Prehabilitation in 108 participants. Currently enrolling.

Timeline

3 January 2023

Primary endpoint
31 August 2025

31 August 2025

Quick facts

Lead sponsor	Nova Scotia Health Authority
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	108
Start date	3 January 2023
Primary completion	31 August 2025
Estimated completion	31 August 2025
Sites	1 location across Canada

Drugs / interventions tested

• Prehabilitation Exercise Intervention

Conditions studied

• Prehabilitation — all drugs for Prehabilitation →
• Exercise — all drugs for Exercise →
• Frailty — all drugs for Frailty →
• Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Nova Scotia Health Authority — full company profile →

Who can join

18 and older, female only, with Prehabilitation or Exercise. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Individuals with ovarian cancer have very poor survival rates. This is because the cancer is not usually detected until it has reached advanced stages. How long an individual survives also is determined by the cancer treatment they receive. Although there are best treatment practices to improve survival, some women have other conditions that limit treatment options. One such condition seen in as many as 50% of women with advanced ovarian cancer is frailty (an age-related decline in function and health). This is a major concern as doctors will often have to change how the cancer is treated based on the patient being frail. For example, patients living with frailty are less likely to have their full tumor removed during surgery. They are also more likely to have complications with surgery, stay in the hospital longer, and recover less well from surgery overall. Patients living with frailty also are more likely to experience delays in their chemotherapy starting, receive lower doses of chemotherapy and/or receive fewer cycles of chemotherapy. These changes in treatment may decrease how long a patient survives after diagnosis. Thus, research is needed to explore strategies to decrease frailty in patients who require treatment for advanced ovarian cancer. An option gaining more attention is physical exercise (e.g. walking, repeatedly rising from a chair). Exercise performed before surgery, which is called prehabilitation, can improve how well a patient recovers after surgery and increase how long they survive. Research has shown that prehabilitation is very beneficial for patients undergoing surgery for heart disease. However, it is not clear whether prehabilitation works for those with advanced ovarian cancer that are going to have surgery. Therefore, the investigators want to explore how a 4+ week exercise program performed while waiting for surgery for advanced ovarian cancer changes frailty and how a patient recovers after surgery. The investigators will specifically look whether the exercise program: 1) reduces how frail a patient is before surgery; 2) improves how well the patient recovers after surgery; and 3) affects the patient's chemotherapy treatment plan. This study will provide important information about the ability of prehabilitation exercise to improve surgical and treatment outcomes in women with advanced ovarian cancer. Overall, it is believed that exercise has the potential to improve the survival of advanced ovarian cancer patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.